Filtered By:
Source: The Lancet Neurology
Condition: Stroke
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 244 results found since Jan 2013.
Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study
Publication date: Available online 28 November 2014 Source:The Lancet Neurology Author(s): Johann Willeit , Theresa Geley , Johannes Schöch , Heinrich Rinner , Andreas Tür , Hans Kreuzer , Norbert Thiemann , Michael Knoflach , Thomas Toell , Raimund Pechlaner , Karin Willeit , Natalie Klingler , Silvia Praxmarer , Michael Baubin , Gertrud Beck , Klaus Berek , Christian Dengg , Klaus Engelhardt , Thomas Erlacher , Thomas Fluckinger , Wilhelm Grander , Josef Grossmann , Hermann Kathrein , Norbert Kaiser , Benjamin Matosevic , Heinrich Matzak , Markus Mayr , Robert Perfler , Werner Poewe , Alexandra Rauter , Gudrun Schoen...
Source: The Lancet Neurology - December 8, 2014 Category: Neurology Source Type: research
Covering all the bases to improve acute stroke care
Publication date: Available online 28 November 2014 Source:The Lancet Neurology Author(s): Steven R Levine
Source: The Lancet Neurology - December 8, 2014 Category: Neurology Source Type: research
Chronic kidney disease and stroke
Publication date: November 2014 Source:The Lancet Neurology, Volume 13, Issue 11 Author(s): Cheng-Yang Hsieh , Huey-Juan Lin , Chih-Hung Chen , Edward Chia-Cheng Lai , Yea-Huei Kao Yang
Source: The Lancet Neurology - October 17, 2014 Category: Neurology Source Type: research
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT00349622. Findings Stage 3 included 66 participants from stages 1 and 2 and 448 new participants. In total, 340 participants were randomly allocated to ceftriaxone and 173 to placebo. During stages 1 and 2, mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0·51 units per month, 95% CI 0·02 to 1·00; p=0·0416), but in stage 3 functional decline between the treatment groups did not differ (0·09, −0·06 to 0·24; p=0·2370). No significant differences in survival between the groups were recorde...
Source: The Lancet Neurology - October 17, 2014 Category: Neurology Source Type: research
